局部晚期胰腺癌标准或高剂量放化疗联合或不联合蛋白酶抑制剂奈非那韦:SCALOP-2 1期/随机2期试验
多中心两阶段SCALOP-2试验评估局部晚期胰腺癌经四周期吉西他滨/白蛋白结合型紫杉醇后,巩固放化疗剂量递增或联用蛋白酶抑制剂奈非那韦能否改善结局。1期确定奈非那韦与标准剂量放化疗同用的最大耐受剂量;2期159例随机比较标准与高剂量放化疗联合或不联合奈非那韦。高剂量放化疗未改善总生存,奈非那韦未改善无进展生存。
要点
- 高剂量与标准剂量放化疗相比总生存无改善,调整后HR 1.13(60%CI 0.91-1.40;p=0.68)。
- 奈非那韦与对照相比无进展生存无改善,调整后HR 1.71(60%CI 1.38-2.12;p=0.98)。
- 高剂量放化疗12个月局部进展数值上低于标准剂量,两组3/4级不良事件率和治疗依从性无差异。
核心结论
- 剂量递增放化疗作为局部晚期胰腺癌巩固治疗可能改善局部肿瘤控制且耐受性良好,但不影响总生存。
- 奈非那韦不改善无进展生存。
研究设计与样本
- 多中心两阶段SCALOP-2试验(ISRCTN50083238),纳入局部晚期胰腺癌患者,先行四周期吉西他滨/白蛋白结合型紫杉醇。
- 1期从27例患者中确定奈非那韦与标准剂量放化疗(50.4 Gy/28次)同用的最大耐受剂量。
- 2期159例患者进入开放标签随机对照比较:标准剂量与高剂量(60 Gy/30次)放化疗,联合或不联合最大耐受剂量奈非那韦。
主要发现
- 高剂量放化疗未改善总生存:16.9个月(60%CI 16.2-17.7)vs 15.6个月(60%CI 14.3-18.2),调整后HR 1.13(60%CI 0.91-1.40;p=0.68)。
- 奈非那韦未改善中位无进展生存:10.0个月(60%CI 9.9-10.2)vs 11.1个月(60%CI 10.3-12.8),调整后HR 1.71(60%CI 1.38-2.12;p=0.98)。
- 12个月局部进展高剂量放化疗数值上低于标准剂量:11/46(23.9%)vs 15/45(33.3%)。
- 奈非那韦或放疗剂量递增均未影响治疗依从性或3/4级不良事件率。
- 治疗后28周内各治疗组间健康相关生活质量评分无持续差异。
关键数值与推荐
- 剂量递增主要结局为总生存,奈非那韦主要结局为无进展生存,次要终点包括健康相关生活质量。
- 标准剂量放化疗为50.4 Gy/28次,高剂量放化疗为60 Gy/30次。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The multi-centre two-stage SCALOP-2 trial (ISRCTN50083238) assessed whether dose escalation of consolidative chemoradiotherapy (CRT) or concurrent sensitization using the protease inhibitor nelfinavir improve outcomes in locally advanced pancreatic cancer (LAPC) following four cycles of gemcitabine/nab-paclitaxel. METHODS: In stage 1, the maximum tolerated dose (MTD) of nelfinavir concurrent with standard-dose CRT (50.4 Gy in 28 fractions) was identified from a cohort of 27 patients. In stage 2, 159 patients were enrolled in an open-label randomized controlled comparison of standard versus high dose (60 Gy in 30 fractions) CRT, with or without nelfinavir at MTD. Primary outcomes following dose escalation and nelfinavir use were respectively overall survival (OS) and progression free survival (PFS). Secondary endpoints included health-related quality of life (HRQoL). RESULTS: High dose CRT did not improve OS (16.9 (60 % confidence interval, CI 16.2-17.7) vs. 15.6 (60 %CI 14.3-18.2) months; adjusted hazard ratio, HR 1.13 (60 %CI 0.91-1.40; p = 0.68)). Similarly, median PFS was not improved by nelfinavir (10.0 (60 %CI 9.9-10.2) vs. 11.1 (60 %CI 10.3-12.8) months; adjusted HR 1.71 (60 %CI 1.38-2.12; p = 0.98)). Local progression at 12 months was numerically lower with high-dose CRT than with standard dose CRT (n = 11/46 (23.9 %) vs. n = 15/45 (33.3 %)). Neither nelfinavir nor radiotherapy dose escalation impacted on treatment compliance or grade 3/4 adverse event rate. There were no sustained differences in HRQoL scores between treatment groups over 28 weeks post-treatment. CONCLUSIONS: Dose-escalated CRT may improve local tumour control and is well tolerated when used as consolidative treatment in LAPC but does not impact OS. Nelfinavir use does not improve PFS.
引用
- Mukherjee S, Qi C, Shaw R, et al. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. Eur J Cancer. 2024. PMID: 39059185. doi:10.1016/j.ejca.2024.114236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。